Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-65

The importance difference between this trial and the Chinese's trial is that all 12 patients were on a ventilator!!!! Can't wait to see more detail whether these patients were conscious or their conditions prior to REMESTEMCEL-L treatment.

Note with the recent published data of 2634 patients, "373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. Mortality for those requiring mechanical ventilation was 88.1%."
https://jamanetwork.com/journals/jama/fullarticle/2765184

There was 282 deaths among 320 patients on ventilator (88.1% of 320p). This means that another 271 patients (49%) died without a ventilator. I wonder if our Phase II/III trials will include those whom are very sick, but was not intubated? The design of the trial will dictate how many patients can be treated with MSCs. I am thinking of many poorer countries that do not have many ventilators/ICU/Hospital specialists/Drugs to treat Covid-19 patients.

We should be proud!!! Our investment saves lives